Arcellx acquired by Gilead; anito-cel's FDA decision on December 23, 2026 determines whether the $5 CVR tied to $6B cumulative sales is realized

Bull

A positive FDA decision on December 23, 2026 would grant anito-cel approval in 4L+ RRMM, enabling Gilead to launch commercially and begin accumulating the $6B in cumulative net sales required by December 31, 2029 to trigger the $5 CVR. The iMMagine-1 data supporting the BLA are compelling — 96% ORR, 74% CR/sCR, 82% 12-month PFS, and a clean neurotoxicity profile with no delayed neurological events — which meaningfully de-risks a standard approval without label restrictions or a complete response letter.

Bear

A complete response letter or approval with a narrow, restrictive label would delay or impair commercial uptake, making the $6B cumulative sales threshold difficult to reach within the 2029 deadline and effectively eliminating the $5 CVR. The most likely failure modes include an FDA request for additional manufacturing or CMC data, concerns about the single-arm nature of iMMagine-1 without a randomized comparator, or a label that excludes subpopulations (e.g., heavily pre-treated penta-refractory patients), limiting addressable market.